Polyphenolic compounds in the Mediterranean diet have received increasing attention due to their protective properties in amyloid neurodegenerative and many other diseases. Here, we have demonstrated for the first time that polyphenol oleuropein aglycone (OleA), which is the most abundant compound in olive oil, has multiple potencies for the inhibition of amyloid self-assembly of pro-inflammatory protein S100A9 and the mitigation of the damaging effect of its amyloids on neuroblastoma SH-SY5Y cells. OleA directly interacts with both native and fibrillar S100A9 as shown by intrinsic fluorescence and molecular dynamic simulation. OleA prevents S100A9 amyloid oligomerization as shown using amyloid oligomer-specific antibodies and cross-β-sheet formation detected by circular dichroism. It decreases the length of amyloid fibrils measured by atomic force microscopy (AFM) as well as reduces the effective rate of amyloid growth and the overall amyloid load as derived from the kinetic analysis of amyloid formation. OleA disintegrates already preformed fibrils of S100A9, converting them into nonfibrillar and nontoxic aggregates as revealed by amyloid thioflavin-T dye binding, AFM, and cytotoxicity assays. At the cellular level, OleA targets S100A9 amyloids already at the membranes as shown by immunofluorescence and fluorescence resonance energy transfer, significantly reducing the amyloid accumulation in GM1 ganglioside containing membrane rafts. OleA increases overall cell viability when neuroblastoma cells are subjected to the amyloid load and alleviates amyloid-induced intracellular rise of reactive oxidative species and free Ca2+. Since S100A9 is both a pro-inflammatory and amyloidogenic protein, OleA may effectively mitigate the pathological consequences of the S100A9-dependent amyloid-neuroinflammatory cascade as well as provide protection from neurodegeneration, if used within the Mediterranean diet as a potential preventive measure.
Polyphenolic compounds in the Mediterranean diet have received increasing attention due to their protective properties in amyloid neurodegenerative and many other diseases. Here, we have demonstrated for the first time that polyphenol oleuropein aglycone (OleA), which is the most abundant compound in olive oil, has multiple potencies for the inhibition of amyloid self-assembly of pro-inflammatory protein S100A9 and the mitigation of the damaging effect of its amyloids on neuroblastoma SH-SY5Y cells. OleA directly interacts with both native and fibrillar S100A9 as shown by intrinsic fluorescence and molecular dynamic simulation. OleA prevents S100A9 amyloid oligomerization as shown using amyloid oligomer-specific antibodies and cross-β-sheet formation detected by circular dichroism. It decreases the length of amyloid fibrils measured by atomic force microscopy (AFM) as well as reduces the effective rate of amyloid growth and the overall amyloid load as derived from the kinetic analysis of amyloid formation. OleA disintegrates already preformed fibrils of S100A9, converting them into nonfibrillar and nontoxic aggregates as revealed by amyloid thioflavin-T dye binding, AFM, and cytotoxicity assays. At the cellular level, OleA targets S100A9 amyloids already at the membranes as shown by immunofluorescence and fluorescence resonance energy transfer, significantly reducing the amyloid accumulation in GM1 ganglioside containing membrane rafts. OleA increases overall cell viability when neuroblastoma cells are subjected to the amyloid load and alleviates amyloid-induced intracellular rise of reactive oxidative species and free Ca2+. Since S100A9 is both a pro-inflammatory and amyloidogenic protein, OleA may effectively mitigate the pathological consequences of the S100A9-dependent amyloid-neuroinflammatory cascade as well as provide protection from neurodegeneration, if used within the Mediterranean diet as a potential preventive measure.
Alzheimer’s disease (AD) and Parkinson’s
disease
(PD) as well as other amyloid-related neurodegenerative ailments are
age-related multifaceted pathological conditions in which a broad
range of events lead to the impairment of brain activity with cognitive
disability as the main clinical hallmark. The majority of nonfamilial
neurodegenerative diseases are characterized by gradual development,
usually spanning many years, and with the appearance of their clinical
signs at the later stage, when cell decay is obvious and cannot be
reversed. In spite of numerous efforts to understand the specific
molecular and cellular mechanisms underlying AD and PD pathologies
and their potential triggers, effective disease-modifying treatments
still remain elusive. Therefore, the delay of the disease onset by
a healthy lifestyle and diet remains the best strategy.Neuroinflammation
and amyloid burden are two characteristic pathologies
of AD, PD, and other neurodegenerative disorders.[1−3] The amyloid
cascade is linked to the failure of polypeptides to adopt and retain
their native structure and function, leading to their conversion into
toxic amyloid oligomers and insoluble amyloid deposits. The amyloid
conversion impairs the physiological function of native polypeptide
and leads to a gain in amyloid cytotoxicity. The latter further interferes
with signaling pathways and cell homeostasis, including redox equilibrium,
free Ca2+ level, and proteostasis.[4] Distinct polypeptides are associated with particular human disorders,
notably the Aβ peptide with AD and α-synuclein with PD;
however, the growth and deposition of amyloids are shared features
of numerous amyloid neurodegenerative diseases.[2] Previously, neuroinflammation was viewed as a reaction
to the degeneration process; however, presently, it is known that
neuroinflammation may play a central role in triggering and promoting
neurodegeneration, since inflammation processes in the brain environment
may promote amyloid self-assembly. In AD and PD, the affected tissues
in the brain display a range of damaging responses, including substantial
activation of microglia and an increase in the level of inflammatory
cytokines, which sustain inflammation and exacerbate neurodegeneration.[5−8]Recently, we have reported that the pro-inflammatory and amyloidogenic
protein S100A9 is a major contributor to both the amyloid and neuroinflammatory
cascades in AD, PD, and traumatic brain injury; importantly, traumatic
brain injury may play a role of the precursor state for numerous neurodegenerative
conditions. Thus, S100A9 may bridge the amyloid self-assembly and
inflammation into the distinctive and common neurodegenerative disease
feature: the amyloid-neuroinflammatory cascade.[9−11] S100A9 has
been described as an alarmin implicated in numerous signaling pathways
in cancers and inflammation-related diseases.[12,13] The high level of S100A9 expression was also observed in malaria,[14] ischemia,[15] obesity,[16] and cardiovascular disease.[17] The S100A9 mRNA was found to be abundant in numerous aged
mammalian organs, also involving the central nervous system; consequently,
it was suggested that an age-associated inflammation is implicated
and persists due to continued S100A9 production.[18]Previously, we have found that S100A9 is a very amyloidogenic
protein;
i.e., in vitro S100A9 aggregates easily under a physiological
environment, and its self-assembly is well-defined by a nucleation-autocatalytic
growth model.[19] The S100A9 self-assembly
into amyloids results in acquired cytotoxicity, exceeding the levels
of Aβ peptide amyloid cytotoxicity in AD[11] and α-synuclein amyloid cytotoxicity in PD.[10] This implies that the increased level of S100A9
persisting during inflammation may provoke its amyloid self-assembly,
deposition, and tissue damage, which we observed in neurodegenerative
diseases,[10,11] in the aged prostate,[20] and in the cell model for S100A8 and S100A9 amyloid accumulation.[21] Indeed, in AD, S100A9 coassembles with Aβ,
leading to intracellular amyloid accumulation and extracellular amyloid
plaque growth;[11] in PD, S100A9 coaggregates
with α-synuclein, which is manifested in Lewy body development,[10] while in traumatic brain injury, S100A9 protein
deposits into numerous precursor plaques.[9] We have found also that S100A9 levels in CSF of AD and mild cognitive
impairment match those of Aβ, further confirming its involvement
in the amyloid-neuroinflammatory cascade even at the disease preclinical
and mild stages.[22] Thus, S100A9 may easily
aggregate by itself or coaggregate with various other proteins and
peptides involved in the amyloid-related diseases and may be considered
as an object for therapeutic treatments. This is particularly important,
since the whole amyloid cascade may be potentially affected or reversed
by targeting the amyloid self-assembly of its single component, such
as the S100A9 protein.Despite significant efforts over the
past decades, there are still
no drugs available to modify amyloid neurodegenerative disease progression,
and despite many compounds being characterized by promising amyloid
inhibiting properties in in vitro experiments, they
failed in the clinical trials. Many low molecular weight substances,
peptides, and various antibodies were examined as prospective amyloid
modifiers, yet potent, natural compounds without significant side
effects are still needed for effective therapeutic treatments.Numerous clinical trials and population analysis support the notion
that the Mediterranean diet correlates with a decreased occurrence
of age-related ailments, such as neurodegenerative disorders.[23−25] The most important characteristic of the Mediterranean diet is the
high consumption of natural plant phenols[24] found in many plant products, such as extra virgin olive oil (EVOO).
Oleuropein is a secoiridoid glycoside containing phenylpropanoid alcohol,
which can be produced from the biosynthesis of mevalonic acid. After
the maturation process and extraction of EVOO, as a result of the
β-glucosidase enzyme activity, this secoiridoid is found in
its aglyconic form as oleuropein aglycone (OleA) (Figure ). Oleuropein and its derivatives
found in EVOO received particular attention due to their multiple
important and protective functionalities, including antioxidant, antiviral,
antitumor, antimicrobial, cardioprotective, hepatoprotective, neuroprotective,
antiaging, antidiabetic, and anti-inflammatory effects.[23] Olive polyphenols, such as OleA and its main
metabolite hydroxytyrosol, were studied for many years by us and other
researchers regarding their effects on the aggregation pathways of
various polypeptides involved in amyloid and neurodegenerative diseases,
including Aβ peptide, tau protein, amylin, transthyretin, and
α-synuclein.[24−31] While multiple effects of olive polyphenols have been detected at
the molecular, cellular, and animal model levels, the specific mechanisms
remain elusive, and important questions still need to be addressed
as to whether there is a generic target or numerous targets along
multiple aggregation pathways, which could be individual for each
particular polypeptide. In particular, the reduced toxicity of the
amyloids developed in the olive polyphenol presence was demonstrated
in both cellular and murine models. In cultured cells, their amyloid
protection was very significant and started at the level of the cellular
membrane, perturbing various signaling pathways.[32,33] The experiments were carried out also on the TgCRND8 transgenic
mouse model of plaque deposition; the mice were fed daily with an
OleA or HT-integrated diet, and it was revealed that the animals displayed
a strong improvement of the memory and behavioral deficits compared
to untreated littermates.[34] These were
accompanied by a substantial decrease in the quantities of amyloid
plaques and the level of neuroinflammation. Moreover, a strong activation
of the autophagic response was detected[34] with possible involvement of epigenetic modifications.[35]
Figure 1
Schematic presentation of the chemical structure of oleuropein
and oleuropein aglycon (OleA).
Schematic presentation of the chemical structure of oleuropein
and oleuropein aglycon (OleA).Here, we studied the effect produced by OleA on S100A9 amyloid
aggregation using a range of complementary methods in biophysics,
biochemistry, cell biology, and advanced microscopy. We demonstrated
how OleA mitigates S100A9 amyloid cytotoxicity in the human neuroblastoma
SH-SY5Y cell line. Altogether, these findings shed light on the molecular
and cellular determinants of OleA protection from toxic amyloids,
highlighting the potential of olive polyphenols in averting AD and
other neurodegenerative diseases associated with the amyloid-neuroinflammatory
cascade.
Results and Discussion
Inhibiting S100A9 Amyloid Aggregation by
OleA
The kinetics
of S100A9 amyloid formation in the presence of increasing OleA concentrations
were carried out using the thioflavin-T (ThT) fluorescence assay as
described previously[36] and shown in Figure A. S100A9 alone assembles
into amyloid structures by the nucleation-dependent polymerization
mechanism,[19,37] and its kinetics are characterized
by the lack of a significant lag phase and steep growth phase, prior
to reaching the plateau level. Upon an increase in the OleA concentrations,
the slopes of amyloid growth, reflecting the kinetics rates, as well
as the plateau levels where the amyloid assembly reached semiequilibrium
noticeably decreased.OleA incubated alone under the same conditions
did not interact with ThT as shown in Figure S1 and therefore did not contribute to the overall ThT signal in the
corresponding mixtures. The initial parts of the S100A9 amyloid kinetic
traces, corresponding to <20% maximal ThT fluorescence intensity
values, were fitted using the nucleation-dependent polymerization
model[38] (Figure B). The effective amyloid growth rate constants
as well as the plateau levels were significantly decreased upon the
increase in OleA concentrations (Figure C,D), reflecting the decrease in the overall
amount of self-assembled amyloids.
Figure 2
Inhibition of S100A9 amyloid formation
in the presence of increasing
OleA concentrations observed by the ThT fluorescence assay and AFM.
(A) S100A9 amyloid kinetics in the presence of increasing OleA concentrations
monitored by the ThT assay. (B) Fitting of the initial parts of S100A9
amyloid kinetics with the nucleation-dependent polymerization model.
(C) Ratios of the effective rate constants of S100A9 amyloid kinetics
in the presence and absence of OleA (B0 is the effective rate constant in the absence of OleA, and B(c) is the rate constant at an OleA concentration
of c). (D) Ratios of plateau intensities of S100A9
amyloid kinetics in the presence and absence of OleA (I0 is the plateau intensity in the absence of OleA, and I(c) is the plateau intensity at an OleA
concentration of c). AFM images of S100A9 amyloid
species without OleA and with increasing OleA concentrations after
a 6 h (E–H) and 48 h (I–L) incubation, respectively.
Amyloid fibril length distributions without OleA and with increasing
OleA concentrations after a 6 h (M–P) and 48 h (Q–S)
incubation, respectively, measured in AFM images. (T) Median length
of S100A9 amyloid fibrils after a 6 h (black circles) and 48 h (red
triangles) incubation, respectively, with increasing OleA concentrations.
Molar ratios of S100A9 to OleA and the time of incubation are indicated
in the figures. 100 μM S100A9, PBS, pH 7.4, and 42 °C. z-scale in the AFM images is indicated on the right with
the bar color gradient from dark brown to light yellow. x,y-AFM scan sizes are 2 × 2 μm.
Inhibition of S100A9 amyloid formation
in the presence of increasing
OleA concentrations observed by the ThT fluorescence assay and AFM.
(A) S100A9 amyloid kinetics in the presence of increasing OleA concentrations
monitored by the ThT assay. (B) Fitting of the initial parts of S100A9
amyloid kinetics with the nucleation-dependent polymerization model.
(C) Ratios of the effective rate constants of S100A9 amyloid kinetics
in the presence and absence of OleA (B0 is the effective rate constant in the absence of OleA, and B(c) is the rate constant at an OleA concentration
of c). (D) Ratios of plateau intensities of S100A9
amyloid kinetics in the presence and absence of OleA (I0 is the plateau intensity in the absence of OleA, and I(c) is the plateau intensity at an OleA
concentration of c). AFM images of S100A9 amyloid
species without OleA and with increasing OleA concentrations after
a 6 h (E–H) and 48 h (I–L) incubation, respectively.
Amyloid fibril length distributions without OleA and with increasing
OleA concentrations after a 6 h (M–P) and 48 h (Q–S)
incubation, respectively, measured in AFM images. (T) Median length
of S100A9 amyloid fibrils after a 6 h (black circles) and 48 h (red
triangles) incubation, respectively, with increasing OleA concentrations.
Molar ratios of S100A9 to OleA and the time of incubation are indicated
in the figures. 100 μM S100A9, PBS, pH 7.4, and 42 °C. z-scale in the AFM images is indicated on the right with
the bar color gradient from dark brown to light yellow. x,y-AFM scan sizes are 2 × 2 μm.To monitor amyloid morphology during the amyloid
self-assembly
process, the atomic force microscopy (AFM) imaging was performed after
a 6 and 48 h incubation of S100A9 samples in the presence and absence
of OleA concentrations as demonstrated in Figure E–L. Already after a 6 h incubation,
S100A9 alone formed flexible fibrils with ca. 2 nm height in the AFM
cross sections and 0.28 ± 0.15 μm median length (Figure E,M). After a 48
h incubation, S100A9 fibrils grew in length, showing a broad distribution
with 0.7 ± 0.4 μm median length, and collapsed and clumped
aggregates were formed (Figure I,Q). Indeed, it has been demonstrated previously that S100A9
flexible fibrils tend to clump upon prolonged incubation.[39] Upon incubation with increasing OleA concentrations,
the length and relative quantity of S100A9 amyloid fibrils captured
by AFM imaging decreased after both 6 and 48 h incubation periods
as demonstrated in Figure T. Importantly, the fibrils do not grow further upon increasing
the incubation time from 6 to 48 h as summarized by presenting the
median values of fibrillar length at different OleA concentrations
in Figure T. The distributions
of fibrillar length in the presence of OleA becomes significantly
narrower compared to S100A9 alone (Figure M–S). The AFM heights of S100A9 fibrils
in all samples remain about the same, ca. 2 nm, in the AFM cross sections.
Interestingly, the decrease in fibrillar length in the presence of
OleA correlates with the reduction of total amount of amyloids detected
by ThT binding (Figure D,T).The dot blot analysis indicates that the interaction
of S100A9
aggregated samples with generic antiamyloid oligomer specific A11
antibodies is noticeable after a 6 h incubation and subsides upon
an increase in the OleA concentration, being completely abolished
at a S100A9 to OleA molar ratio of 1:10 (Figure S2). After a 48 h incubation, the amount of oligomeric species
was significantly diminished in the S100A9 amyloid sample in the absence
of OleA and completely absent in the presence of all concentrations
of OleA.Interestingly, upon the addition of OleA to preformed
S100A9 fibrils
assembled during the 48 h incubation, we observed the decrease of
ThT fluorescence, indicating the decrease of amyloid quantity in these
samples (Figure A).
AFM imaging demonstrated that flexible fibrils of S100A9 observed
prior to the addition of OleA (Figure B) have collapsed into nonfibrillar aggregates after
the addition of OleA, i.e., at a 1:2 molar ratio of S100A9 to OleA
(Figure C).
Figure 3
Preformed S100A9
fibrils disintegrated by OleA. (A) Decrease of
ThT dye fluorescence upon the addition of OleA to S100A9 fibrils formed
after a 48 h incubation. (B) AFM images of S100A9 fibrils without
OleA. (C) AFM image of S100A9 aggregates after the addition of 137
μM OleA to the sample shown in (B). 75 μM S100A9 was subjected
to fibrillation in PBS, pH 7.4, at 42 °C. Scan sizes are 2.5
× 2.5 μm.
Preformed S100A9
fibrils disintegrated by OleA. (A) Decrease of
ThT dye fluorescence upon the addition of OleA to S100A9 fibrils formed
after a 48 h incubation. (B) AFM images of S100A9 fibrils without
OleA. (C) AFM image of S100A9 aggregates after the addition of 137
μM OleA to the sample shown in (B). 75 μM S100A9 was subjected
to fibrillation in PBS, pH 7.4, at 42 °C. Scan sizes are 2.5
× 2.5 μm.The far-UV circular dichroism
(CD) spectrum of native S100A9 is
characteristic for α-helical protein, displaying minima at 222
and 208 nm, and it was not perturbed upon the addition of OleA (Figure ). This indicates
that OleA perturbs the S100A9 structure locally rather than globally.
The spectrum of fibrillated S100A9 displayed some changes in its shape
with a broad minimum of ellipticity at 214–216 nm, reflecting
the development of the β-sheet. It is not excluded that some
α-helical structure was preserved in the S100A9 fibrils, since
the spectrum is broader then the typical β-sheet spectrum; i.e.,
the remaining α-helices still can be packed at the fibrillar
interface. When S100A9 was incubated in the presence of OleA to induce
its amyloid formation, the shape of the CD spectrum remained close
to the native-like one, demonstrating that OleA indeed inhibits amyloid
development. Interestingly, when OleA was added to the preformed fibrils
of S100A9, it induced the changes in the far-UV CD spectrum, which
resembles a mixture of α-helices and β-sheets. This indicates
that some reduction of the β-sheet content took place (Figure ), which corresponds
to the nonfibrillar aggregate formation described above (Figure ).
Figure 4
Far-UV CD spectra of
native and amyloid S100A9 and the OleA effect
on them. Spectra were recorded at 25 °C at the following conditions:
75 μM S100A9 in all samples and 1:2 S100A9 to OleA molar ratio,
if OleA is added. PBS, pH 7.4. S100A9 fibrils were formed during the
48 h incubation at 42 °C. Labeling of the samples is shown in
the legend.
Far-UV CD spectra of
native and amyloid S100A9 and the OleA effect
on them. Spectra were recorded at 25 °C at the following conditions:
75 μM S100A9 in all samples and 1:2 S100A9 to OleA molar ratio,
if OleA is added. PBS, pH 7.4. S100A9 fibrils were formed during the
48 h incubation at 42 °C. Labeling of the samples is shown in
the legend.Thus, all above experiments demonstrate
consistently that OleA
produces a significant inhibiting effect on S100A9 amyloid formation
by inhibiting its amyloid oligomerization (dot blot analysis with
A11 antibodies) and cross-β-sheet formation (far-UV CD), reducing
the effective rate of amyloid assembly (kinetic assay), reducing the
length of amyloid fibrils (AFM), and thus diminishing the overall
quantity of the amyloids (ThT fluorescence and AFM). Moreover, OleA
is able to convert the already preformed S100A9 fibrils into unstructured
aggregates and potentially make them more susceptible to the clearance
process in the body.
Interaction of OleA with Native and Amyloid
S100A9 followed
by Intrinsic Fluorescence
To shed light on OleA interactions
with native and amyloid S100A9, we have titrated both samples with
increasing concentrations of OleA and followed the changes by the
intrinsic fluorescence of Trp 88. For the titration, we used the S100A9
amyloid sample incubated for 24 h at a 100 μM concentration
and subsequently diluted it to 4 μM to prevent fibrillar clumping
(Figure ), and native
S100A9 was also taken at 4 μM (both in monomer equivalent).
In both samples, we have observed a decrease of the intrinsic fluorescence
intensities upon an increase in the OleA concentrations, demonstrating
nonhyperbolic concentration dependences, which were fitted with a
two binding site model as shown in Figure A–C. Both fitting curves were largely
overlapped, suggesting the same binding sites in the native and amyloid
S100A9 species. Since OleA itself can associate into dimer, trimer,
and larger species[40] and act as a fluorescence
quencher of Trp fluorescence,[29] the apparent
dissociation constants (Kd) of 0.5 and
200 μM may reflect the cumulative effect of binding and fluorescence
quenching produced by the OleA polymorphic species.
Figure 5
Interaction of native
and amyloid S100A9 with OleA monitored by
intrinsic fluorescence. Fluorescence spectra of native (A) and amyloid
(B) S100A9 upon increasing concentrations of OleA. (C) Relative fluorescence
intensities at the spectral maximum of native (blue triangles) and
amyloid (red circles) S100A9 upon increasing OleA concentrations.
Fitting curves are shown by solid lines in the corresponding color.
The two binding site model is shown in the inset. (D) Shifts of fluorescence
spectral maxima of native and amyloid S100A9 determined by the first
derivative method upon increasing OleA concentrations shown in the
same symbols as in (C). Four μM S100A9, PBS, pH 7.4, and 42
°C.
Interaction of native
and amyloid S100A9 with OleA monitored by
intrinsic fluorescence. Fluorescence spectra of native (A) and amyloid
(B) S100A9 upon increasing concentrations of OleA. (C) Relative fluorescence
intensities at the spectral maximum of native (blue triangles) and
amyloid (red circles) S100A9 upon increasing OleA concentrations.
Fitting curves are shown by solid lines in the corresponding color.
The two binding site model is shown in the inset. (D) Shifts of fluorescence
spectral maxima of native and amyloid S100A9 determined by the first
derivative method upon increasing OleA concentrations shown in the
same symbols as in (C). Four μM S100A9, PBS, pH 7.4, and 42
°C.Interestingly, native and amyloid
S100A9 are characterized by different
fluorescence maxima of 343 and 337 nm, respectively, indicating that
within the fibrils Trp 88 is present in the more hydrophobic environment.
The fluorescence spectral maxima of both native and amyloid S100A9
samples were shifted by ca. 3 nm toward the shorter wavelengths upon
an increase in the OleA concentrations (Figure D), indicating that in both species Trp 88
becomes even more buried into the hydrophobic interior upon OleA binding.
MD Simulation of the OleA Interaction with S100A9
To
shed further light on OleA interactions with S100A9, we have performed
the MD simulation of the native S100A9 dimer in the presence of two
molecules of monomeric OleA, taking into account that S100A9 self-assembles
into a homodimer under native and also destabilizing conditions[11,37] (Figure ). The S100A9
dimer is characterized by a flat surface with no deep cavities, and
molecular docking reveals only one major OleA binding site per subunit
(Figure A). The B-factor
presentation of the S100A9 molecules shows that OleA docks into the
least mobile part of the S100A9 structure (Figure B).[41] The space
filling presentation of the S100A9 dimer with the hydrophobic and
charged/hydrophilic residues indicates that OleA binds in a shallow
hydrophobic cavity in each subunit (Figure C) by forming several dynamic H bonds (Figure D). Specifically,
these are the hydrogen bonds between S100A9 Glu 72 and the OH group
on the OleA aromatic ring, Glu 52, and methyl-ester end of OleA as
well as Arg 85 and the carbonyl oxygen on OleA (Figure D). In addition, π–π stacking
interactions between the Trp 88 and OleA aromatic ring are formed
(Figure D). The number
of dynamic hydrogen bonds per time frame between each OleA molecule
and S100A9 subunit varies between 1 and 3 (Figure E), which together with π–π
stacking interactions may ensure micromolar to submicromolar binding
affinities, observed in the fluorescence titration measurements (Figure ). The root mean
square deviation (RMSD) graph demonstrates that, due to the lack of
a well-defined binding cavity, OleA molecules may dissociate from
the S100A9 dimer after ca. 15 ns (Figure F). The high mobility of OleA at the S100A9
surface can disrupt the optimal protein–ligand orientations
and the maximal number of binding interactions, suggesting that OleA
binding may involve multiple events. The high-affinity interactions
reflect the optimal ligand–protein orientation and the maximal
number of binding interactions, while the suboptimal orientation and
lower number of binding interactions may contribute to the lower binding
affinities, consistent with the fluorescence titration experiments
(Figure ). OleA binding
to the S100A9 dimer does not perturb its α-helical secondary
structure beyond the binding site, which is consistent with the CD
measurements described above.
Figure 6
MD simulation of the interactions of native
S100A9 with OleA. (A)
Binding of one OleA molecule per subunit of S100A9 dimer. S100A9 monomers
are shown by the ribbon diagram in yellow and green colors, respectively.
The amino acid side chains of S100A9, which form binding interactions
with OleA, are shown by cyan sticks. OleA molecules are shown by magenta
sticks. OleA forms hydrogen bonds with Glu 52 and Arg 85 and π–π
stacking interactions with Trp 88. (B) B-factor presentation of the
S100A9 dimer backbone shows that OleA (in black sticks) binds to the
protein site with low mobility (shown in blue). The loops with high
mobility are shown by thicker tubes with a color gradient from yellow
to red, corresponding to increasing mobility. (C) S100A9 dimer surface
presentation in space filling and colors based on the polarity of
the amino acid residues: hydrophilic residues, blue; hydrophobic residues,
brown; residues with intermediate properties, white. OleA (shown by
sticks) binds to a shallow hydrophobic cavity on the S100A9 surface.
(D) Detailed presentation of the OleA orientation and binding interactions
(presented in yellow) highlighting: π–π stacking
between Trp 88 and OleA, hydrogen bonding between Arg 85 and the carbonyl
oxygen of OleA, and the proximity between Glu 52 and the ester group
of OleA. (E) Number of hydrogen bonds between each OleA molecule and
S100A9 dimer. OleA molecules dissociate when the number of hydrogen
bonds falls to zero. Hydrogen bonds were defined as the interactions
between the polar groups with an angle of less than 20° and less
than 3.0 Å distance. (F) Root mean square deviation (RMSD) values
demonstrating the mobility of each OleA molecule and S100A9 dimer.
Ligand dissociation results in the rapid increase in the RMSD values.
MD simulation of the interactions of native
S100A9 with OleA. (A)
Binding of one OleA molecule per subunit of S100A9 dimer. S100A9 monomers
are shown by the ribbon diagram in yellow and green colors, respectively.
The amino acid side chains of S100A9, which form binding interactions
with OleA, are shown by cyan sticks. OleA molecules are shown by magenta
sticks. OleA forms hydrogen bonds with Glu 52 and Arg 85 and π–π
stacking interactions with Trp 88. (B) B-factor presentation of the
S100A9 dimer backbone shows that OleA (in black sticks) binds to the
protein site with low mobility (shown in blue). The loops with high
mobility are shown by thicker tubes with a color gradient from yellow
to red, corresponding to increasing mobility. (C) S100A9 dimer surface
presentation in space filling and colors based on the polarity of
the amino acid residues: hydrophilic residues, blue; hydrophobic residues,
brown; residues with intermediate properties, white. OleA (shown by
sticks) binds to a shallow hydrophobic cavity on the S100A9 surface.
(D) Detailed presentation of the OleA orientation and binding interactions
(presented in yellow) highlighting: π–π stacking
between Trp 88 and OleA, hydrogen bonding between Arg 85 and the carbonyl
oxygen of OleA, and the proximity between Glu 52 and the ester group
of OleA. (E) Number of hydrogen bonds between each OleA molecule and
S100A9 dimer. OleA molecules dissociate when the number of hydrogen
bonds falls to zero. Hydrogen bonds were defined as the interactions
between the polar groups with an angle of less than 20° and less
than 3.0 Å distance. (F) Root mean square deviation (RMSD) values
demonstrating the mobility of each OleA molecule and S100A9 dimer.
Ligand dissociation results in the rapid increase in the RMSD values.Thus, the combined fluorescence titration and MD
simulation experiments
demonstrate consistently that OleA indeed interacts with native S100A9.
The interactions involve multiple binding events due to the lack of
specific OleA binding cavities on the S100A9 molecule (Figure C) similar to its interactions
with other previously studied amyloidogenic polypeptides.[24,26,29,32] Moreover, OleA can self-assemble into a larger species,[40] which may also affect its apparent binding affinity.
These were further supported by the similar binding of OleA with both
native and amyloid S100A9 (Figure C).
OleA Alleviates S100A9 Induced Cytotoxicity
Measured by the
MTT Assay
The effect of OleA on the S100A9 cytotoxicity induced
in the neuroblastoma SH-SY5Y cell line was studied by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cytotoxicity assay. Initially, neuroblastoma cells were
treated for 24 h with various concentrations of S100A9 alone in either
native or 48 h aged amyloid form (Figure S3A). S100A9 amyloids were more cytotoxic, reducing the cell viability
by ca. 40–50% at 20 to 40 μM concentrations; native S100A9
also reduced the cell viability by ca. 20–30% at similar concentrations
(Figure S3A). Since S100A9 is an alarmin
and pro-inflammatory protein, it can induce cellular toxicity also
in its native state via activation of RAGE and TLR-4 receptors.[42,43]Then, SH-SY5Y cells were exposed for 24 h to 20 μM of
either native or amyloid S100A9 samples aged for 24 and 48 h, respectively,
under aggregating conditions (Figure A). All samples were prepared both without or with
OleA at the following S100A9 to OleA molar ratios: 1:1, 1:2, 1:5,
and 1:10 (in monomeric equivalent). Using the MTT test, we found that
the S100A9 amyloids aged 24 and 48 h without OleA displayed the same
cytotoxic effect, decreasing cell viability by about 40% (Figure A). Their cytotoxicity
was mitigated, however, if S100A9 aggregates were incubated in the
presence of OleA, then the cell viability was fully recovered at both
1:5 and 1:10 of S100A9 to OleA molar ratios (Figure A). Similar trend was observed for native
S100A9, where the recovery of cytotoxicity correlated with the increasing
concentrations of OleA, and full recovery was achieved at a 1:5 of
S100A9 to OleA molar ratio.
Figure 7
Cytotoxic effect of the S100A9 amyloids in the
SH-SY5Y cells is
mitigated by OleA. (A) Viability of SH-SY5Y cells measured by the
MTT assay and (B) ROS levels in the SH-SY5Y cells measured by DCFDA
fluorescence. Cells were exposed to 20 μM S100A9 samples for
24 h. S100A9 was added in either native or amyloid forms, which were
incubated for 24 and 48 h in PBS, pH 7.4, at 42 °C, respectively,
prior the addition to the cells. S100A9 to OleA molar ratios were
1:0, 1:1, 1:2, 1:5, and 1:10 as indicated along x-axis. The control corresponds to the untreated cells and is shown
by a single black bar, where the absence of S100A9 and OleA is indicated
as (0:0). The experimental bars corresponding to the addition of native
S100A9 are shown in black, the addition of 24 h aged S100A9 amyloids
are shown in gray, and the 48 h aged amyloids are shown in white.
Error bars indicate the standard error of the mean of the independent
experiments carried out in triplicate. ***p <
0.001 and **p < 0.01 versus control (0:0). °p < 0.05 and °°p < 0.01
versus cell viability in the presence of native or the corresponding
aggregated S100A9 without OleA, i.e., molar ratio (1:0). (C) Confocal
microscopy imaging of the intracellular free Ca2+ levels
in the SH-SY5Y cells exposed for 10, 30, and 60 min to 20 μM
S100A9 amyloids incubated for 48 h in the absence or in the presence
of OleA at the molar ratios of S100A9 to OleA indicated in the figure.
Scale bars are 14 μm in all images.
Cytotoxic effect of the S100A9 amyloids in the
SH-SY5Y cells is
mitigated by OleA. (A) Viability of SH-SY5Y cells measured by the
MTT assay and (B) ROS levels in the SH-SY5Y cells measured by DCFDA
fluorescence. Cells were exposed to 20 μM S100A9 samples for
24 h. S100A9 was added in either native or amyloid forms, which were
incubated for 24 and 48 h in PBS, pH 7.4, at 42 °C, respectively,
prior the addition to the cells. S100A9 to OleA molar ratios were
1:0, 1:1, 1:2, 1:5, and 1:10 as indicated along x-axis. The control corresponds to the untreated cells and is shown
by a single black bar, where the absence of S100A9 and OleA is indicated
as (0:0). The experimental bars corresponding to the addition of native
S100A9 are shown in black, the addition of 24 h aged S100A9 amyloids
are shown in gray, and the 48 h aged amyloids are shown in white.
Error bars indicate the standard error of the mean of the independent
experiments carried out in triplicate. ***p <
0.001 and **p < 0.01 versus control (0:0). °p < 0.05 and °°p < 0.01
versus cell viability in the presence of native or the corresponding
aggregated S100A9 without OleA, i.e., molar ratio (1:0). (C) Confocal
microscopy imaging of the intracellular free Ca2+ levels
in the SH-SY5Y cells exposed for 10, 30, and 60 min to 20 μM
S100A9 amyloids incubated for 48 h in the absence or in the presence
of OleA at the molar ratios of S100A9 to OleA indicated in the figure.
Scale bars are 14 μm in all images.The cytotoxicity of the preformed fibrils of S100A9 treated with
OleA was also tested on the SH-SY5Y cells by the MTT assay. The results
are shown in Figure S4. We observed a decrease
of the cytotoxic effect of the preformed S100A9 amyloids when they
were treated with OleA at a 1:2 molar ratio of S100A9 to OleA from
1 to 48 h. This data suggests that after 48 h of coincubation OleA
disassembles already formed S100A9 fibrils into nonfibrillar aggregates
as shown in Figure C, that are no longer toxic. Such an inhibitory effect was also observed
after shorter treatment times, suggesting that OleA likely makes the
fibrils harmless by solvating them before inducing their collapse
into unstructured aggregates.
OleA Mitigates the Perturbations
in Reactive Oxidative Species
(ROS) and Intracellular Ca2+ Levels Induced by S100A9 Amyloids
Free Ca2+ levels and reactive oxidative species imbalances
are involved in the cellular toxicity of amyloid.[44,45] Here, we examined whether OleA can act as a protective agent in
these processes as well. Intracellular ROS levels were measured using
the fluorescent probe CM-H2DCFDA (Figure B). In the cells exposed to native S100A9
as well as to the 24 and 48 h aged S100A9 amyloids, the ROS levels
were increased by ca. 1.5-, 2.0-, and 2.8-fold, respectively, compared
to untreated cells. Remarkably, the presence of OleA reduced ROS production
in all cells exposed to both native and amyloid S100A9. The ROS level
returned to the level of untreated cells at 1:5 and 1:10 ratios of
S100A9 to OleA (Figure B).We evaluated the changes of intracellular free Ca2+ levels in neuroblastoma cells treated with native S100A9 and S100A9
amyloids aged for 24 and 48 h using confocal microscopy with the Fluo-3-acetoxymethyl
ester (Fluo-3AM) Ca2+ indicator (Figure S3B). Native S100A9 did not cause an increase in the free Ca2+ level after the addition to SH-SY5Y cells from 10 to 60
min, while both aged amyloid samples led to a similar increase of
intracellular Ca2+, which was manifested in Fluo-3AM fluorescence
(Figure S3B). Therefore, in further experiments,
only the 48 h aged S100A9 samples were used with increasing OleA concentrations
(Figure C). When the
cells were treated with a 1:1 molar ratio of S100A9 to OleA, Fluo-3AM
fluorescence subsided significantly. Remarkably, it returned to the
level of untreated cells when SH-SY5Y cells were exposed to the samples
with 1:5 and 1:10 of S100A9 to OleA molar ratios. This is consistent
with the protective effect of OleA observed by MTT cell viability
and the ROS assays presented above (Figure A,B).
Effect of S100A9 Amyloids
on Differentiated SH-SY5Y Neuroblastoma
Cells
To compare the susceptibility of undifferentiated and
differentiated SH-SY5Y cells to S100A9 amyloids, we repeated the MTT
and ROS assays on differentiated SH-SY5Y cells. The cells were exposed
for 24 h to 20 μM S100A9 fibrils (equivalent of the monomer
concentration). The differentiated cells appeared to be slightly more
susceptible to the amyloid induced damage in terms of both cell viability
and ROS production (Figure S5). In agreement
with our unpublished data, the different cell susceptibility could
be due to a different poly- and monosialic acid expression on the
plasma membrane. However, in this paper, we focused on the undifferentiated
SH-SY5Y cells to compare our results with previously published studies.[11]
OleA Interferes with S100A9 Amyloid Binding
to Cell Membrane
Rafts Studied by Immunofluorescence and Fluorescence Resonance Energy
Transfer (FRET)
The direct binding of amyloids to plasma
membranes is a critical step in amyloid cytotoxicity.[46,47] Notably, amyloids can accumulate in membrane rafts, containing monosialotetrahexosylganglioside-1
(GM1).[48] The amyloid binding leads to structural
and functional perturbations of the cell membrane, affecting signaling
pathways[49−51] and altering intracellular free Ca2+ and
ROS levels.[44,52] In addition, many papers have
reported the effect on signaling pathways by direct binding of amyloids
to cell membrane receptors.[52−55] Therefore, we performed immunofluorescence assay
with the GM1 and S100A9 specific fluorescently labeled antibodies
using confocal microscopy and sensitized FRET analysis to evaluate
the interactions between the membrane ganglioside GM1 and S100A9 amyloids
produced after the 48 h incubation in the absence or presence of OleA.
Confocal imaging revealed that the amyloid assemblies were accumulated
at the SH-SY5Y plasma membrane and colocalized with GM1 rafts (Figure A,E). Moreover, a
strong FRET signal indicates close spatial localization and even direct
interactions of the S100A9 amyloids with the membrane GM1 (Figure I). When the cells
were subjected to S100A9 amyloids developed at increasing OleA concentrations,
we observed both smaller clusters of aggregates on the cell membrane
(Figure F–H)
and a reduced FRET signal (Figure J–L). Furthermore, to assess the direct involvement
of ganglioside GM1 in the binding of S100A9 amyloids to the cell membrane,
we also conducted immunofluorescence experiments after treating the
cells with the ganglioside synthesis inhibitor d-threo-1-phenil-2-decanoylamino-3-morpholino-1-propanol
(d-PDMD). We found that the binding of S100A9 fibrils to membrane
rafts was significantly reduced in cells depleted of GM1, following
their treatment with d-PDMD (Figure M,N). These data support the conclusion that the binding
sites of S100A9 amyloids to the cell membrane occur at the raft domains.
These observations also suggest the critical role of GM1 in binding
of S100A9 amyloids to the cell membrane, most likely due to the clusters
of sialic acid moieties, producing negatively charged regions at the
cell surface. All results signify the roles of the amyloid–membrane
interactions in triggering cellular toxicity and the importance of
OleA in reducing cytotoxicity and perturbations of intracellular Ca2+ and ROS levels induced by S100A9 amyloids.
Figure 8
Immunolocalization of
S100A9 aggregates on the SH-SY5Y plasma membrane.
Confocal microscopy imaging of SH-SY5Y cells exposed for 24 h to 20
μM S100A9 aggregated for 48 h in the absence or in the presence
of different molar ratios of S100A9 to OleA as indicated in the figures.
The cell membranes were stained with Alexa 488-conjugated CTX-B (green
fluorescence); cell nuclei were stained with Hoechst 33342 (blue fluorescence),
and protein aggregates were stained with anti-S100A9 antibodies followed
by treatment with Alexa 568-conjugated antirabbit secondary antibodies
(red fluorescence). The mergence of the channels is shown in (A–D).
Zoomed areas from (A–D) are shown in (E–H). FRET efficiency
in those areas is shown in (I–L). (M) S100A9 do not bind to
membrane rafts in the SH-SY5Y cells pretreated with an inhibitor of
the GM1 synthesis as revealed by the lack of FRET efficiency. The
control corresponds to the untreated cells. The SH-SY5Y cells were
pretreated with 10 μM PDMD for 48 h (indicated as CTRL-PDMP)
to reduce GM1 on the cell surface and then incubated for 24 h with
20 μM S100A9 fibrils (in monomer concentration). (N) Quantification
of green fluorescence per cell, indicating the reduction of GM1 in
cell membranes. Error bars indicate the standard error of three independent
experiments. *p < 0.001 versus control.
Immunolocalization of
S100A9 aggregates on the SH-SY5Y plasma membrane.
Confocal microscopy imaging of SH-SY5Y cells exposed for 24 h to 20
μM S100A9 aggregated for 48 h in the absence or in the presence
of different molar ratios of S100A9 to OleA as indicated in the figures.
The cell membranes were stained with Alexa 488-conjugated CTX-B (green
fluorescence); cell nuclei were stained with Hoechst 33342 (blue fluorescence),
and protein aggregates were stained with anti-S100A9 antibodies followed
by treatment with Alexa 568-conjugated antirabbit secondary antibodies
(red fluorescence). The mergence of the channels is shown in (A–D).
Zoomed areas from (A–D) are shown in (E–H). FRET efficiency
in those areas is shown in (I–L). (M) S100A9 do not bind to
membrane rafts in the SH-SY5Y cells pretreated with an inhibitor of
the GM1 synthesis as revealed by the lack of FRET efficiency. The
control corresponds to the untreated cells. The SH-SY5Y cells were
pretreated with 10 μM PDMD for 48 h (indicated as CTRL-PDMP)
to reduce GM1 on the cell surface and then incubated for 24 h with
20 μM S100A9 fibrils (in monomer concentration). (N) Quantification
of green fluorescence per cell, indicating the reduction of GM1 in
cell membranes. Error bars indicate the standard error of three independent
experiments. *p < 0.001 versus control.
Concluding Remarks
Here, for the
first time, we have demonstrated that the most abundant
polyphenol in olive oil, OleA, has multiple potencies in the inhibition
of the amyloid self-assembly of pro-inflammatory protein S100A9 and
mitigation of its damaging effect on neuroblastoma SH-SY5H cells.
By directly interacting with native and fibrillar S100A9, OleA acts
via multiple mechanisms and pathways to inhibit S100A9 amyloid aggregation;
i.e., it prevents amyloid oligomerization and cross-β-sheet
formation, reduces the effective rate of amyloid growth and the length
of amyloid fibrils, and diminishes the overall amyloid load. Moreover,
OleA is able to disintegrate already preformed fibrils of S100A9,
converting them into nontoxic aggregates, which do not bind ThT dye,
characteristic for cross-β-sheet amyloids. Furthermore, OleA
targets S100A9 amyloids at the cellular membrane, protecting cells
from amyloid cytotoxicity and amyloid-induced increased levels of
ROS and free Ca2+. Since S100A9 is both a pro-inflammatory
and amyloidogenic protein, OleA effectively mitigates the pathological
consequences of the S100A9-driven amyloid-neuroinflammatory cascade
in neurodegenerative diseases.[9−11] Together with previously reported
antiamyloid effects of OleA on other amyloidogenic polypeptides,[25−33] the present findings further emphasize the beneficial properties
of the Mediterranean diet in which olive oil is a central component.
Methods
Amyloid Fibril Formation
S100A9 protein was expressed
in E. coli and subjected to purification procedures
as reported previously.[56] Lyophilized S100A9
was dissolved in PBS buffer at pH 7.4, with all solutions remaining
on ice. In order to remove any aggregates, all S100A9 solutions were
filtered through a 0.22 μm spin membrane filter prior to subjecting
them to the amyloid incubation. To form amyloids, S100A9 was incubated
in PBS, pH 7.4, at 42 °C. Previously, we have conducted extensive
kinetics experiments on S100A9 amyloid formation at both 37 and 42
°C[19] as well as at 55 °C.[57] The scaling of the corresponding kinetics rate
constants versus temperature illustrated that the mechanism of S100A9
amyloid self-assembly remained the same in this wide temperature range,
which is below the thermal unfolding transition of S100A9, occurring
above 60 °C.[56] The morphology of amyloid
fibrils, developed in this temperature range and followed by AFM,
remained also the same.[19,57] We selected the arbitrary
condition at 42 °C in this research to speed up the amyloid self-assembly
without altering the basic mechanism.
Preparation of OleA
Oleuropein (extrasynthese) was
deglycosylated by subjecting it to almond β-glucosidase treatment
(EC 3.2.1.21, Fluka, Sigma-Aldrich) as specified previously.[27] 10 mM oleuropein in 310 μL of 0.1 M sodium
phosphate buffer, pH 7.0, was incubated with 8.9 IU of β-glucosidase
overnight at room temperature (RT) and centrifuged at 18 000
rpm for 10 min. The pellet containing the deglycosylated OleA was
resuspended in 100 mM stocks using DMSO, frozen, protected from light,
and once opened, used within 24 h. The deglycosylation was verified
by assaying in the supernatant the levels of glucose using the Glucose
assay kit (HK, Sigma-Aldrich).
Dissolving OleA
OleA was dissolved in 20% DMSO to reach
a 50 mM concentration. A second dilution was made in 200 μL
of PBS to reach a 5 mM concentration of OleA. Samples were sonicated
during 2 min to dissolve the entire sample and manipulated at RT in
the dark during the experiments. In the concentration-dependent experiments,
OleA was subsequently diluted to 100, 200, 500, and 1000 μM.
The same percentage of DMSO (0.4%) was kept in all solutions.
ThT Fluorescence
Assay
ThT is a fluorescence dye that
binds to the β-sheet containing amyloid structures; this leads
to an increase of its fluorescence and thus enables the kinetics of
amyloid formation to be followed and quantified. The ThT assay was
performed as described previously.[36] 100
μM S100A9 was transferred into Corning 96 black well plates
with transparent bottoms, and then, 20 μM ThT was added to every
well. Sample volumes were kept at 200 μL per well. The 96 well
plates were covered, transferred immediately into a Tecan F200 PRO
plate reader, and subjected to incubation at 42 °C during 50
h by applying 432 rpm orbital shaking every 10 min. Fluorescence of
ThT dye was recorded every 10 min. A filter at 430 nm was used for
excitation, and a filter at 495 nm was used for emission; both filters
were characterized by 20 nm band widths. All protein solutions were
incubated in triplicates.
AFM Imaging
AFM imaging was performed
in air using
a BioScope Catalyst AFM (Bruker) operating in a peak force mode. The
scan rate was set at 0.51 Hz, and a scan resolution of 512 ×
512 pixels was used. Bruker MSLN and SLN cantilevers were used in
all measurements. Imaging was also conducted using a PicoPlus AFM
(Molecular Imaging) equipped with a 100 μm scanner operating
in tapping mode in air. The resonance frequency was set in the 170
to 190 kHz range; the scan rate was at 1 Hz, and the scan resolution
was at 512 × 512 pixels. For ambient AFM imaging, 20 μL
samples were deposited on freshly cleaved mica, kept for 30 min, washed
5 times with 200 μL deionized water, and left to dry at RT.
The heights of the amyloid structures were measured in their AFM cross
sections using Bruker Nanoscope AFM analysis software, and the amyloid
fibril lengths were measured using ImageJ software.
Dot Blot Analysis
S100A9 amyloid samples incubated
with and without OleA were examined in dot blot experiments using
amyloid oligomer specific antibodies.[58] 2 μL of the amyloid sample was deposited on a nitrocellulose
membrane (Fisher Thermo Scientific) and dried at RT for 15 min. Nonspecific
antigen sites were blocked using 3% bovine serum albumin (BSA) in
Tris buffer saline containing 0.05% Tween-20 (TBS-T) for 1.5 h at
RT. Then, the nitrocellulose membrane was subjected to incubation
with primary antibodies, i.e., rabbit A11 generic amyloid oligomer
specific antibodies produced by Kayed et al.,[58] and dissolved in 0.5% BSA in TBS-T for 30 min at RT. After that,
the nitrocellulose membrane was washed 3 times with TBS-T for 5 min
each wash and incubated with the secondary antibodies, i.e., antirabbit
IgGs conjugated with horseradish peroxidase (AS10668 lot 1809 Agrisea),
for 45 min at a 1:500 dilution at RT. The nitrocellulose membrane
was washed 2 times with TBS-T and 1 time with TBS for 15 min each
wash. After the addition of enhanced chemiluminescence reagent for
1 min, the membrane was subjected to the measurement of chemiluminescence
by a Bio-Rad ChemiDoc Imaging System. The density of blots was measured
using an ImageJ software.
Titration of Native and Aggregated S100A9
by OleA Using Intrinsic
Fluorescence
4 μM samples of either native or 24 h
aged amyloid S100A9 were titrated by OleA in a 2 mm path length quartz
cuvette using degassed PBS, pH 7.4, at RT. Intrinsic fluorescence
spectra were acquired using a FP 6500 Jasco spectrofluorometer at
RT. Excitation wavelength was set at 280 nm; fluorescence emission
was recorded between 295 and 450 nm, and both excitation and emission
slits were set at 3 nm. The spectra were obtained by averaging 3 scans
recorded at a 200 nm/min rate. The OleA spectra at each added concentration
were subtracted from those of S100A9.
Titration of S100A9 Amyloids
by OleA Monitored by ThT Fluorescence
150 μM S100A9
was aggregated for 48 h in degassed PBS, pH
7.4, at 42 °C. 20 μM ThT was added to each amyloid sample;
then, they were diluted to a 75 μM S100A9 concentration. The
titration by OleA was performed using 2 mm quartz cuvettes in a FP
6500 Jasco spectrofluorometer at RT. Excitation wavelength was set
at 450 nm; fluorescence emission spectra were recorded between 480
and 550 nm, and both slits at excitation and emission were set at
10 nm. The spectra were obtained by averaging 3 scans recorded at
a 200 nm/min rate.
Fitting the Kinetics of S100A9 Amyloid Formation
in the Absence
and Presence of OleA
The S100A9 amyloid kinetics in the absence
and presence of OleA were fitted using a nucleation dependent polymerization
model.[38] The initial parts (<20% plateau
level) of the kinetic curves were fitted using the following equation:where I0 is the
fluorescence intensity at the <20% plateau level and B0 is the effective rate constant, combining microscopic
nucleation and growth constants.
Fitting the Titration of
S100A9 by OleA Monitored by Intrinsic
Fluorescence
The maximum positions of the fluorescence spectra
of S100A9, containing a single Trp 88 residue, were determined using
a first derivative method. Prior to this, all spectra were smoothed
by the Eilers smoothing algorithm, minimizing the noise level.[59] The smoothing parameter λ was 105, and the smoothing order was 3. The fluorescence intensity at the
spectral maximum and the spectral maximum position errors were calculated
by taking into account the instrument accuracy (Jasco FP6500), and
3 spectral replicates were recorded at each OleA concentration. The
titration curve of S100A9 by OleA followed by fluorescence intensity
at the spectral maximum was fitted by the two binding site model,[60] relating four parameters:where F is the fluorescence
intensity of S100A9 in the presence of each OleA concentration, F0 is the fluorescence intensity of S100A9 in
the absence of OleA, f1 is the fractional
occupancy of binding sites with affinity K1, and f2 is the fractional occupancy
of binding sites with affinity K2.
Far-UV
CD
CD spectra were recorded using a Jasco J-810
spectropolarimeter. The measurements were performed in a quartz cuvette
with 1 mm spectral pathway, and 3 repeats were averaged.
MD
All atom MD calculations used the GROMACS 2019.3
program and protocols that were descried in our earlier studies.[37]
Molecular Docking Studies
Possible
binding sites for
OleA on the S100A9 surface were at first explored by searching for
hydrophobic patches and cavities on the protein Connolly surface.[61] Docking positions were calculated using RxDock
and AutoDock Vina 1.1.2.[62,63] The ligands were hydrogenated
and charged at pH 7.0 using the Gasteiger protocol. Proteins were
protonated at pH 7.0 using the AMBER98S force field. The molecular
structures for OleA were taken from ChemSpider and PubChem databases.
The S100A9 structure was downloaded from the protein data bank, PDB: 5I8N.
All-Atom Molecular
Dynamics Studies
For MD computation,
the S100A9-OleA complex was prepared using CHARMM-GUI solution builder.[64] In our simulations, we used 85 080 water
molecules (TIP3), 272 potassium ions (POT), and 221 chlorine ions
(CLA). The simulation box was 112 × 112 × 112 Å3 in size and contained 254 871 atoms. The system was
relaxed using a sequence of equilibration steps at 303.15 K using
Nose-Hoover coupling, and the pressure was set to 1.0 bar using semi-isotropic
Parinello-Rahman coupling. The constraint algorithm was LINCS, and
the cutoff scheme was Verlet. Two minimization steps and one equilibration
step were used for the system relaxation. The simulations analyzed
molecular processes for 100 ns on a molecular time scale in 50 million
steps with the step size set to 2 fs. The ligand parametrization was
prepared using ACPYPE tools[65] or the CHARMM-GUI
Ligand Reader & Modeler for the calculation of CHARMM-compatible
topology and parameter files.[66] All simulations
used GROMACS version 2019.4.[67]
Neuroblastoma
Cell Culture
Human neuroblastoma SH-SY5Y
cells were grown in a 5.0% CO2 humidified atmosphere at
37 °C in 50% HAM, 50% DMEM, containing 10% fetal bovine serum
(FBS), 3.0 mM glutamine, 100 units/mL penicillin, and 100 μg/mL
streptomycin. The materials used for cell culture were from Sigma-Aldrich.
To assess cell viability by the MTT reduction assay, neuroblastoma
cells were grown in a 96 well plate at 15 × 103 cells/well,
while for immunofluorescence staining, they were cultured in a 24
well plate at 3 × 104 cells/well. The nuclei of the
cells were stained with 0.5 μg/mL Hoechst 33342 (Sigma-Aldrich)
during a 30 min incubation at 37 °C; then, the cells were rinsed
twice with PBS, and complete medium was added.
Differentiating
Neuroblastoma Cells
SH-SY5Y cell differentiation
was induced by growing the cells for 7 days in culture medium supplemented
with 3% FBS and 10 μM retinoic acid,[68] and then, the cells were treated with S100A9 amyloids.
MTT Viability
Assay
The MTT cell metabolomic activity
assay optimized for the SH-SY5Y cell line was performed to assess
the cell viability. First, the neuroblastoma cell line was seeded
and grown for 24 h in 96 well plates in complete medium. Then, the
cells were treated for 24 h with 20 μM S100A9 in the native
or aggregated state in the absence or presence of increasing OleA
concentrations. After 24 h of coincubation of the cells with protein
samples, the culture medium from each well was discarded and the cells
were incubated for a further 1 h at 37 °C with 100 μL of
serum free without phenol red DMEM containing 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) dye. Subsequently, cells were lysed by adding 100 μL
of solubilizing solution (20% SDS, 50% N,N-dimethylformamide). After 2 h of lysis at 37 °C,
the absorbance value of blue formazan, produced by viable cells, was
determined by a spectrophotometric microplate reader at 570 nm. The
average values were calculated from triplicate readings and subtracted
from the blank value.
Intracellular ROS Levels
Intracellular
ROS levels were
measured using fluorescent probe 2′,7′-dichlorofluorescein
diacetate acetyl ester (CM-H2DCFDA, Thermo Fisher Scientific),
which permeates the cell membrane and then becomes hydrolyzed and
oxidized by radical species to fluorescent product, DCF. The formation
of this product was monitored by the increase of fluorescence at 538
nm. SH-SY5Y cells were seeded in 96 well plates (3 × 104 cells/well) and, after 24 h, were exposed during a further 24 h
to 20 μM S100A9 in the native or aggregated form with or without
increasing OleA concentrations. After that, DMEM, without phenol red
and supplemented with 10 μM CM-H2DCFDA, was added
to each well, and the samples were incubated for 30 min in the dark
at 37 °C. The fluorescence at 538 nm was measured using a Fluoroscan
Ascent FL (Thermo Fisher Scientific).
Cytosolic Levels of Free
Calcium Measured by Confocal Imaging
Fluorescent probe Fluo-3
acetoxymethyl ester (Fluo-3, Thermo Fisher
Scientific) was used to detect intracellular levels of free Ca2+. Subconfluent neuroblastoma cells grown on glass coverslips
were loaded with 5.0 μM Fluo-3 at 37 °C for 5 min and then
treated for 10, 30, or 60 min with S100A9 aggregates formed after
a 48 h incubation either without OleA or with OleA at different S100A9
to OleA molar ratios (1:1, 1:5, and 1:10). Finally, the cells were
fixed for 10 min in 2.0% paraformaldehyde in PBS. Imaging was carried
out using a confocal Leica TCS SP8 scanning microscope with a Leica
Plan 7 Apo 40× oil immersion objective.
Immunofluorescence Confocal
Imaging of S100A9 Amyloid Interactions
with Cell Membranes
Subconfluent neuroblastoma cells were
seeded on glass coverslips and exposed for 24 h to 2.0 μM S100A9
amyloids incubated for 48 h either without OleA or with OleA at different
S100A9 to OleA molar ratios (1:1, 1:5, and 1:10). After cell washing
with PBS, gangliosides GM1 in live cell plasma membranes were labeled
with 10 ng/mL cholera toxin B-subunit (CTX-B) conjugated with Alexa
488 (Thermo Fisher Scientific) in fresh complete medium for 10 min
at RT. Cells were subsequently fixed by 2.0% paraformaldehyde in PBS
for 10 min and treated with a 1:1 acetone/ethanol solution for 4.0
min at RT to allow cell permeabilization. After thorough PBS washing,
the blocking was performed using PBS containing 0.5% BSA and 0.2%
gelatin for 1 h at 37 °C. S100A9 in the neuroblastoma cell membranes
was stained for 1.0 h at RT with rabbit anticalgranulin B (B-5) monoclonal
antibody (sc-376772, Santa-Cruz Biotechnology) diluted to 1:300 in
the blocking solution. Then, the cells were washed 3 times with PBS
for 30 min under stirring, and then, Alexa 568 conjugated antirabbit
secondary antibodies (Thermo Fisher Scientific) diluted to 1:100 in
PBS were added for 30 min at RT. Finally, the samples were washed
twice in PBS and once in distilled water, and the coverslips were
mounted. Fluorescence imaging was performed using a Leica TCS SP8
AOBS confocal scanning microscope. Cell imaging was acquired in at
least two different experiments using a Leica HC PL Apo CS2 63×
oil immersion objective. Spectral analysis of the FRET interaction
between Alexa 488 fluorophore conjugated with CTX-B and Alexa 568
fluorophore on immunolabeled S100A9 was carried out by the FRET sensitized
emission method, as previously reported.[32,69]
Statistical Analysis
One-way analysis of variance by
ANOVA and pairwise comparisons by the Tukey HSD (honestly significant
difference) method were used for the statistical evaluation of the
data.